Renoprotective effects of febuxostat compared with allopurinol in patients with hyperuricemia: A systematic review and meta-analysis
Hyperuricemia is reported to be related to rapid progression of renal function in patients with chronic kidney disease (CKD). Allopurinol, a uric acid lowering agent, protects renal progression. However, it is not widely used in patients with CKD because of its serious adverse event. Febuxostat can...
Saved in:
| Published in | Kidney research and clinical practice Vol. 36; no. 3; pp. 274 - 281 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Korea (South)
Korean Society of Nephrology
01.09.2017
The Korean Society of Nephrology 대한신장학회 |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2211-9132 2211-9140 |
| DOI | 10.23876/j.krcp.2017.36.3.274 |
Cover
Loading…
| Abstract | Hyperuricemia is reported to be related to rapid progression of renal function in patients with chronic kidney disease (CKD). Allopurinol, a uric acid lowering agent, protects renal progression. However, it is not widely used in patients with CKD because of its serious adverse event. Febuxostat can be alternatively used for patients who are intolerable to allopurinol. We aimed to determine renoprotective effect and urate-lowering effect between the two drugs.
We performed a systematic review and meta-analysis of randomized controlled trials to assess the effects of febuxostat compared to allopurinol in patients with hyperuricemia. MEDLINE, Embase, and Cochrane Library databases were searched to identify research publications.
Four relevant publications were selected from among 3,815 studies. No significant differences were found in the changes in serum creatinine from baseline between the febuxostat and allopurinol groups. Changes in estimated glomerular filtration rate (eGFR) were observed between the two groups at 1 month (mean difference 1.65 mL/min/1.73 m
, 95% confidence interval [CI] 0.38, 2.91 mL/min/1.73 m
; heterogeneity χ
= 1.25, I
= 0%,
= 0.01); however, the changes in eGFR were not significantly different at 3 months. A significant difference did exist in the changes in albuminuria levels from baseline between the febuxostat and allopurinol groups (mean difference -80.47 mg/gCr, 95% CI -149.29, -11.64 mg/gCr; heterogeneity χ
= 0.81, I
= 0%,
= 0.02). A significant difference was also observed in the changes in serum uric acid from baseline between the febuxostat and allopurinol groups (mean difference -0.92 mg/dL, 95% CI -1.29, -0.56 mg/dL; heterogeneity χ
= 6.24, I
= 52%,
< 0.001).
Febuxostat might be more renoprotective than allopurinol. |
|---|---|
| AbstractList | Background: Hyperuricemia is reported to be related to rapid progression of renal function in patients with chronic kidney disease (CKD). Allopurinol, a uric acid lowering agent, protects renal progression. However, it is not widely used in patients with CKD because of its serious adverse event. Febuxostat can be alternatively used for patients who are intolerable to allopurinol. We aimed to determine renoprotective effect and urate-lowering effect between the two drugs. Methods: We performed a systematic review and meta-analysis of randomized controlled trials to assess the effects of febuxostat compared to allopurinol in patients with hyperuricemia. MEDLINE, Embase, and Cochrane Library databases were searched to identify research publications. Results: Four relevant publications were selected from among 3,815 studies. No significant differences were found in the changes in serum creatinine from baseline between the febuxostat and allopurinol groups. Changes in estimated glomerular filtration rate (eGFR) were observed between the two groups at 1 month (mean difference 1.65 mL/min/1.73 m², 95% confidence interval [CI] 0.38, 2.91 mL/min/1.73 m²; heterogeneity χ² = 1.25, I² = 0%, P = 0.01); however, the changes in eGFR were not significantly different at 3 months. A significant difference did exist in the changes in albuminuria levels from baseline between the febuxostat and allopurinol groups (mean difference −80.47 mg/gCr, 95% CI −149.29, −11.64 mg/gCr; heterogeneity χ² = 0.81, I² = 0%, P = 0.02). A significant difference was also observed in the changes in serum uric acid from baseline between the febuxostat and allopurinol groups (mean difference −0.92 mg/dL, 95% CI −1.29, −0.56 mg/dL; heterogeneity χ² = 6.24, I² = 52%, P < 0.001). Conclusion: Febuxostat might be more renoprotective than allopurinol. Hyperuricemia is reported to be related to rapid progression of renal function in patients with chronic kidney disease (CKD). Allopurinol, a uric acid lowering agent, protects renal progression. However, it is not widely used in patients with CKD because of its serious adverse event. Febuxostat can be alternatively used for patients who are intolerable to allopurinol. We aimed to determine renoprotective effect and urate-lowering effect between the two drugs. We performed a systematic review and meta-analysis of randomized controlled trials to assess the effects of febuxostat compared to allopurinol in patients with hyperuricemia. MEDLINE, Embase, and Cochrane Library databases were searched to identify research publications. Four relevant publications were selected from among 3,815 studies. No significant differences were found in the changes in serum creatinine from baseline between the febuxostat and allopurinol groups. Changes in estimated glomerular filtration rate (eGFR) were observed between the two groups at 1 month (mean difference 1.65 mL/min/1.73 m , 95% confidence interval [CI] 0.38, 2.91 mL/min/1.73 m ; heterogeneity χ = 1.25, I = 0%, = 0.01); however, the changes in eGFR were not significantly different at 3 months. A significant difference did exist in the changes in albuminuria levels from baseline between the febuxostat and allopurinol groups (mean difference -80.47 mg/gCr, 95% CI -149.29, -11.64 mg/gCr; heterogeneity χ = 0.81, I = 0%, = 0.02). A significant difference was also observed in the changes in serum uric acid from baseline between the febuxostat and allopurinol groups (mean difference -0.92 mg/dL, 95% CI -1.29, -0.56 mg/dL; heterogeneity χ = 6.24, I = 52%, < 0.001). Febuxostat might be more renoprotective than allopurinol. Hyperuricemia is reported to be related to rapid progression of renal function in patients with chronic kidney disease (CKD). Allopurinol, a uric acid lowering agent, protects renal progression. However, it is not widely used in patients with CKD because of its serious adverse event. Febuxostat can be alternatively used for patients who are intolerable to allopurinol. We aimed to determine renoprotective effect and urate-lowering effect between the two drugs.BACKGROUNDHyperuricemia is reported to be related to rapid progression of renal function in patients with chronic kidney disease (CKD). Allopurinol, a uric acid lowering agent, protects renal progression. However, it is not widely used in patients with CKD because of its serious adverse event. Febuxostat can be alternatively used for patients who are intolerable to allopurinol. We aimed to determine renoprotective effect and urate-lowering effect between the two drugs.We performed a systematic review and meta-analysis of randomized controlled trials to assess the effects of febuxostat compared to allopurinol in patients with hyperuricemia. MEDLINE, Embase, and Cochrane Library databases were searched to identify research publications.METHODSWe performed a systematic review and meta-analysis of randomized controlled trials to assess the effects of febuxostat compared to allopurinol in patients with hyperuricemia. MEDLINE, Embase, and Cochrane Library databases were searched to identify research publications.Four relevant publications were selected from among 3,815 studies. No significant differences were found in the changes in serum creatinine from baseline between the febuxostat and allopurinol groups. Changes in estimated glomerular filtration rate (eGFR) were observed between the two groups at 1 month (mean difference 1.65 mL/min/1.73 m2, 95% confidence interval [CI] 0.38, 2.91 mL/min/1.73 m2; heterogeneity χ2 = 1.25, I2 = 0%, P = 0.01); however, the changes in eGFR were not significantly different at 3 months. A significant difference did exist in the changes in albuminuria levels from baseline between the febuxostat and allopurinol groups (mean difference -80.47 mg/gCr, 95% CI -149.29, -11.64 mg/gCr; heterogeneity χ2 = 0.81, I2 = 0%, P = 0.02). A significant difference was also observed in the changes in serum uric acid from baseline between the febuxostat and allopurinol groups (mean difference -0.92 mg/dL, 95% CI -1.29, -0.56 mg/dL; heterogeneity χ2 = 6.24, I2 = 52%, P < 0.001).RESULTSFour relevant publications were selected from among 3,815 studies. No significant differences were found in the changes in serum creatinine from baseline between the febuxostat and allopurinol groups. Changes in estimated glomerular filtration rate (eGFR) were observed between the two groups at 1 month (mean difference 1.65 mL/min/1.73 m2, 95% confidence interval [CI] 0.38, 2.91 mL/min/1.73 m2; heterogeneity χ2 = 1.25, I2 = 0%, P = 0.01); however, the changes in eGFR were not significantly different at 3 months. A significant difference did exist in the changes in albuminuria levels from baseline between the febuxostat and allopurinol groups (mean difference -80.47 mg/gCr, 95% CI -149.29, -11.64 mg/gCr; heterogeneity χ2 = 0.81, I2 = 0%, P = 0.02). A significant difference was also observed in the changes in serum uric acid from baseline between the febuxostat and allopurinol groups (mean difference -0.92 mg/dL, 95% CI -1.29, -0.56 mg/dL; heterogeneity χ2 = 6.24, I2 = 52%, P < 0.001).Febuxostat might be more renoprotective than allopurinol.CONCLUSIONFebuxostat might be more renoprotective than allopurinol. Background: Hyperuricemia is reported to be related to rapid progression of renal function in patients with chronic kidney disease (CKD). Allopurinol, a uric acid lowering agent, protects renal progression. However, it is not widely used in patients with CKD because of its serious adverse event. Febuxostat can be alternatively used for patients who are intolerable to allopurinol. We aimed to determine renoprotective effect and urate-lowering effect between the two drugs. Methods: We performed a systematic review and meta-analysis of randomized controlled trials to assess the effects of febuxostat compared to allopurinol in patients with hyperuricemia. MEDLINE, Embase, and Cochrane Library databases were searched to identify research publications. Results: Four relevant publications were selected from among 3,815 studies. No significant differences were found in the changes in serum creatinine from baseline between the febuxostat and allopurinol groups. Changes in estimated glomerular filtration rate (eGFR) were observed between the two groups at 1 month (mean difference 1.65 mL/min/1.73 m2, 95% confidence interval [CI] 0.38, 2.91 mL/min/1.73 m2; heterogeneity χ2 = 1.25, I2 = 0%, P = 0.01); however, the changes in eGFR were not significantly different at 3 months. A significant difference did exist in the changes in albuminuria levels from baseline between the febuxostat and allopurinol groups (mean difference -80.47 mg/gCr, 95% CI -149.29, -11.64 mg/gCr; heterogeneity χ2 = 0.81, I2 = 0%, P = 0.02). A significant difference was also observed in the changes in serum uric acid from baseline between the febuxostat and allopurinol groups (mean difference -0.92 mg/dL, 95% CI -1.29, -0.56 mg/dL; heterogeneity χ2 = 6.24, I2 = 52%, P < 0.001). Conclusion: Febuxostat might be more renoprotective than allopurinol. KCI Citation Count: 4 |
| Author | Han, Kum Hyun Han, Sang Youb Kim, Hyun-Jung Um, Tae-Hyun Oh, Se Won Kim, Sollip Cho, Chong-Rae Ahn, Hyeong-Sik |
| AuthorAffiliation | 1 Department of Laboratory Medicine, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea 2 Department of Preventive Medicine, Korea University College of Medicine, Seoul, Korea 3 Department of Internal Medicine, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea |
| AuthorAffiliation_xml | – name: 3 Department of Internal Medicine, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea – name: 1 Department of Laboratory Medicine, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea – name: 2 Department of Preventive Medicine, Korea University College of Medicine, Seoul, Korea |
| Author_xml | – sequence: 1 givenname: Sollip surname: Kim fullname: Kim, Sollip organization: Department of Laboratory Medicine, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea – sequence: 2 givenname: Hyun-Jung surname: Kim fullname: Kim, Hyun-Jung organization: Department of Preventive Medicine, Korea University College of Medicine, Seoul, Korea – sequence: 3 givenname: Hyeong-Sik surname: Ahn fullname: Ahn, Hyeong-Sik organization: Department of Preventive Medicine, Korea University College of Medicine, Seoul, Korea – sequence: 4 givenname: Se Won surname: Oh fullname: Oh, Se Won organization: Department of Internal Medicine, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea – sequence: 5 givenname: Kum Hyun surname: Han fullname: Han, Kum Hyun organization: Department of Internal Medicine, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea – sequence: 6 givenname: Tae-Hyun surname: Um fullname: Um, Tae-Hyun organization: Department of Laboratory Medicine, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea – sequence: 7 givenname: Chong-Rae surname: Cho fullname: Cho, Chong-Rae organization: Department of Laboratory Medicine, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea – sequence: 8 givenname: Sang Youb surname: Han fullname: Han, Sang Youb organization: Department of Internal Medicine, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28904879$$D View this record in MEDLINE/PubMed https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002258103$$DAccess content in National Research Foundation of Korea (NRF) |
| BookMark | eNpVUU1v1DAQjVARLaU_AeQjPWzwVxKHA9Kq4mOlSkhVOUcTe9z1bmIHO9uyd344ZrdU1JcZzXvz5nnmdXHig8eieMtoyYVq6g-bchv1VHLKmlLUpSh5I18UZ5wztmiZpCdPueCnxUVKG5pfrWQr6lfFKVctlappz4rfN-jDFMOMenb3SNDanCUSLLHY736FNMNMdBgniGjIg5vXBIYhTLvofBiI82SC2aHPPQdwvZ8wZlDj6OAjWZK0TzOOmaNJxHuHDwS8ISPOsAAPwz659KZ4aWFIePEYz4sfXz7fXn1bXH__urpaXi90xdi8qBig7lnDTNtIY7huGaKQtbGspYCMV9jrSrZgKVVW0koa7I3AtuFKaoXivLg86vpou612XQB3iHeh28ZueXO76ljL8-aqzF0duSbAppuiGyHuDw2HQoh3HcT8qQE7aXsQBpSyVEuoqWqURFrzyjLKmG2y1qej1rTrRzQ6byvC8Ez0OeLdOnu676qqzaf6a-b9o0AMP3eY5m50SeMwgMewS9m0UKpiVIhMfff_rKch_04u_gABYbYa |
| CitedBy_id | crossref_primary_10_1155_2019_1076189 crossref_primary_10_1016_j_matbio_2018_02_017 crossref_primary_10_1007_s00296_020_04517_4 crossref_primary_10_1159_000512178 crossref_primary_10_1097_MD_0000000000029589 crossref_primary_10_1111_nep_13407 crossref_primary_10_1186_s13075_019_2011_y crossref_primary_10_3390_life13112199 crossref_primary_10_1186_s10020_019_0109_y crossref_primary_10_23876_j_krcp_2017_36_3_207 crossref_primary_10_1080_12298093_2019_1673595 crossref_primary_10_1097_MD_0000000000016311 crossref_primary_10_3892_etm_2018_6972 crossref_primary_10_1186_s40360_023_00723_5 crossref_primary_10_1186_s13075_019_1993_9 crossref_primary_10_3390_cells13050450 crossref_primary_10_1016_j_bcp_2023_115794 crossref_primary_10_3390_medicina57010058 crossref_primary_10_3390_molecules27113521 crossref_primary_10_1371_journal_pone_0264627 crossref_primary_10_2147_OARRR_S282631 crossref_primary_10_5863_1551_6776_29_4_359 crossref_primary_10_1681_ASN_0000000000000326 crossref_primary_10_1186_s12882_022_02850_3 crossref_primary_10_1186_s12933_020_01163_9 crossref_primary_10_3390_molecules25174010 crossref_primary_10_1016_j_dsx_2020_01_007 crossref_primary_10_3389_fphar_2021_690557 crossref_primary_10_4078_jrd_2023_0029 crossref_primary_10_1016_j_ejmech_2019_01_043 crossref_primary_10_3923_ijp_2022_994_1003 crossref_primary_10_3390_nu15020417 crossref_primary_10_1093_ajh_hpy157 crossref_primary_10_3904_kjim_2023_206 crossref_primary_10_1016_j_semarthrit_2022_152073 crossref_primary_10_17650_1818_8338_2024_18_3_K723 crossref_primary_10_1093_mr_roae115 crossref_primary_10_1111_jfbc_14049 crossref_primary_10_1093_rheumatology_keac460 crossref_primary_10_1007_s10067_020_05079_3 |
| ContentType | Journal Article |
| Copyright | Copyright © 2017 by The Korean Society of Nephrology 2017 |
| Copyright_xml | – notice: Copyright © 2017 by The Korean Society of Nephrology 2017 |
| DBID | NPM 7X8 5PM DOA ACYCR |
| DOI | 10.23876/j.krcp.2017.36.3.274 |
| DatabaseName | PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals Korean Citation Index |
| DatabaseTitle | PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2211-9140 |
| EndPage | 281 |
| ExternalDocumentID | oai_kci_go_kr_ARTI_1922215 oai_doaj_org_article_4fba3da88f0c4a608784e0625f1011f7 PMC5592895 28904879 |
| Genre | Journal Article |
| GroupedDBID | .~1 1~. 1~5 4.4 457 4G. 5VS 7-5 8JR AACTN AAEDT AAEDW AAIKJ AALRI AAXUO ABBQC ABMAC ABWVN ACGFS ACRPL ADBBV ADEZE ADMUD ADNMO ADRAZ ADVLN AEKER AEXQZ AGHFR AGYEJ AITUG AJRQY AKRWK ALMA_UNASSIGNED_HOLDINGS AMRAJ AOIJS BAWUL BCNDV DIK EBS EF. EJD FDB FEDTE FNPLU GBLVA GROUPED_DOAJ HVGLF HYE HZ~ IPNFZ KQ8 M41 M48 MO0 NPM O-L OK1 P-8 P-9 PC. PGMZT Q38 RIG ROL RPM SDF SSZ 7X8 5PM 0SF 6I. AAFTH ACYCR HZB NCXOZ |
| ID | FETCH-LOGICAL-c511t-51aecb171d974dd2c91ee346df190ae125ebc549af008f4054debd3e97284c8e3 |
| IEDL.DBID | M48 |
| ISSN | 2211-9132 |
| IngestDate | Tue Jun 25 21:09:10 EDT 2024 Wed Aug 27 01:29:53 EDT 2025 Thu Aug 21 18:03:51 EDT 2025 Fri Jul 11 00:49:40 EDT 2025 Thu Apr 03 07:02:12 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | Hyperuricemia Chronic kidney disease Febuxostat Gout Meta-analysis |
| Language | English |
| License | This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c511t-51aecb171d974dd2c91ee346df190ae125ebc549af008f4054debd3e97284c8e3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Sollip Kim and Hyun-Jung Kim contributed equally to this work. |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.23876/j.krcp.2017.36.3.274 |
| PMID | 28904879 |
| PQID | 1938851033 |
| PQPubID | 23479 |
| PageCount | 8 |
| ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_1922215 doaj_primary_oai_doaj_org_article_4fba3da88f0c4a608784e0625f1011f7 pubmedcentral_primary_oai_pubmedcentral_nih_gov_5592895 proquest_miscellaneous_1938851033 pubmed_primary_28904879 |
| PublicationCentury | 2000 |
| PublicationDate | 2017-09-01 |
| PublicationDateYYYYMMDD | 2017-09-01 |
| PublicationDate_xml | – month: 09 year: 2017 text: 2017-09-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Korea (South) |
| PublicationPlace_xml | – name: Korea (South) |
| PublicationTitle | Kidney research and clinical practice |
| PublicationTitleAlternate | Kidney Res Clin Pract |
| PublicationYear | 2017 |
| Publisher | Korean Society of Nephrology The Korean Society of Nephrology 대한신장학회 |
| Publisher_xml | – name: Korean Society of Nephrology – name: The Korean Society of Nephrology – name: 대한신장학회 |
| References | 28107415 - PLoS One. 2017 Jan 20;12 (1):e0170393 24042021 - Nephrol Dial Transplant. 2014 Feb;29(2):406-13 19729442 - J Am Soc Nephrol. 2010 Mar;21(3):395-7 20370912 - Arthritis Res Ther. 2010;12(2):R63 18799720 - J Am Soc Nephrol. 2008 Dec;19(12):2407-13 20171303 - Int J Surg. 2010;8(5):336-41 11711505 - Hypertension. 2001 Nov;38(5):1101-6 18946066 - N Engl J Med. 2008 Oct 23;359(17):1811-21 23131573 - J Ren Nutr. 2013 Sep;23(5):389-96 25676011 - Clin Exp Nephrol. 2015 Dec;19(6):1044-53 25120316 - J Korean Med Sci. 2014 Aug;29(8):1077-81 25928556 - BMC Nephrol. 2015 Apr 19;16:58 15610247 - Kidney Int. 2005 Jan;67(1):237-47 23676888 - Circ J. 2013;77(8):2043-9 27010159 - Eur Rev Med Pharmacol Sci. 2016 Mar;20(5):983-92 20538833 - Clin J Am Soc Nephrol. 2010 Aug;5(8):1388-93 16377385 - Am J Kidney Dis. 2006 Jan;47(1):51-9 18337481 - J Am Soc Nephrol. 2008 Jun;19(6):1204-11 19237717 - Arch Intern Med. 2009 Feb 23;169(4):342-50 22350467 - Clin Exp Nephrol. 2012 Aug;16(4):549-56 23929928 - Clin J Am Soc Nephrol. 2013 Nov;8(11):1960-7 24152124 - Ren Fail. 2014 Mar;36(2):225-31 26233732 - Am J Kidney Dis. 2015 Dec;66(6):945-50 23024028 - Arthritis Care Res (Hoboken). 2012 Oct;64(10):1431-46 12707287 - Hypertension. 2003 Jun;41(6):1183-90 25048744 - Clin Rheumatol. 2014 Nov;33(11):1643-8 19447778 - Rheumatology (Oxford). 2009 May;48 Suppl 2:ii15-ii19 |
| References_xml | – reference: 12707287 - Hypertension. 2003 Jun;41(6):1183-90 – reference: 23024028 - Arthritis Care Res (Hoboken). 2012 Oct;64(10):1431-46 – reference: 15610247 - Kidney Int. 2005 Jan;67(1):237-47 – reference: 23676888 - Circ J. 2013;77(8):2043-9 – reference: 25676011 - Clin Exp Nephrol. 2015 Dec;19(6):1044-53 – reference: 19729442 - J Am Soc Nephrol. 2010 Mar;21(3):395-7 – reference: 22350467 - Clin Exp Nephrol. 2012 Aug;16(4):549-56 – reference: 18946066 - N Engl J Med. 2008 Oct 23;359(17):1811-21 – reference: 19237717 - Arch Intern Med. 2009 Feb 23;169(4):342-50 – reference: 25048744 - Clin Rheumatol. 2014 Nov;33(11):1643-8 – reference: 27010159 - Eur Rev Med Pharmacol Sci. 2016 Mar;20(5):983-92 – reference: 23131573 - J Ren Nutr. 2013 Sep;23(5):389-96 – reference: 20538833 - Clin J Am Soc Nephrol. 2010 Aug;5(8):1388-93 – reference: 18799720 - J Am Soc Nephrol. 2008 Dec;19(12):2407-13 – reference: 28107415 - PLoS One. 2017 Jan 20;12 (1):e0170393 – reference: 16377385 - Am J Kidney Dis. 2006 Jan;47(1):51-9 – reference: 25928556 - BMC Nephrol. 2015 Apr 19;16:58 – reference: 11711505 - Hypertension. 2001 Nov;38(5):1101-6 – reference: 20370912 - Arthritis Res Ther. 2010;12(2):R63 – reference: 24042021 - Nephrol Dial Transplant. 2014 Feb;29(2):406-13 – reference: 25120316 - J Korean Med Sci. 2014 Aug;29(8):1077-81 – reference: 23929928 - Clin J Am Soc Nephrol. 2013 Nov;8(11):1960-7 – reference: 19447778 - Rheumatology (Oxford). 2009 May;48 Suppl 2:ii15-ii19 – reference: 24152124 - Ren Fail. 2014 Mar;36(2):225-31 – reference: 20171303 - Int J Surg. 2010;8(5):336-41 – reference: 26233732 - Am J Kidney Dis. 2015 Dec;66(6):945-50 – reference: 18337481 - J Am Soc Nephrol. 2008 Jun;19(6):1204-11 |
| SSID | ssj0000684936 ssib060475385 |
| Score | 2.2590709 |
| Snippet | Hyperuricemia is reported to be related to rapid progression of renal function in patients with chronic kidney disease (CKD). Allopurinol, a uric acid lowering... Background: Hyperuricemia is reported to be related to rapid progression of renal function in patients with chronic kidney disease (CKD). Allopurinol, a uric... |
| SourceID | nrf doaj pubmedcentral proquest pubmed |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 274 |
| SubjectTerms | Chronic kidney disease Febuxostat Gout Hyperuricemia Meta-analysis Original 내과학 |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gL4k14ySCuWeLEeZhbQVQFqRwQlXqz_Jihq22dKt2V-AH94R3HLuwiJC6cIiWx5Hgcz_d5Zj4z9rbvOqgcmLKNgUMJypfKClF6P6t_tVj5WJx89LU7PJZfTtqTraO-Yk5YkgdOA_dOojWNN8OAlZOmq4Z-kFARakeaTALnOnLyeVtkKq3Bg1Tz-YA1MZwYXq5T-Q55qD7GNFeTi2qVol803aJZ1L3Mov3kY8KEf8Obf6ZNbvmhg3vsbgaQfD91_D67BeEBu32UQ-QP2dU3CGNWX6CVjOeEDT4iR7Cbn2MsIeI3qec87sPyGHy_iNvu4xlfBp61Vi_Tw1NiqtOsPXS-NO_5Pv8t_sxT4Qs3wfNzWJvSZImTR-z44NP3j4dlPmqhdIS41mUrDDgreuGJX3hfOyUAGtl5JMBggFAQWEdU0iBhBiSQJz1Y34Dqyb25AZrHbC-MAZ4yLo0wWKNTyqK0SAxSdb42LUJtRWuwYB_iOOuLpKaho771fIOsrrPV9b-sXrA3ZCW9csu5fbz-GPVq0sQCPmtCrWT2tmCvb4yo6aeJkRATYNxc0gvNMEQtwaZgT5JRf_UnRl6JxamC9Tvm3unw7pOwPJ2FuYmdUev22f_4wufsTpyeKZ3tBdtbTxt4SfhnbV_NU_0awlIGEw priority: 102 providerName: Directory of Open Access Journals |
| Title | Renoprotective effects of febuxostat compared with allopurinol in patients with hyperuricemia: A systematic review and meta-analysis |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/28904879 https://www.proquest.com/docview/1938851033 https://pubmed.ncbi.nlm.nih.gov/PMC5592895 https://doaj.org/article/4fba3da88f0c4a608784e0625f1011f7 https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002258103 |
| Volume | 36 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | Kidney Research and Clinical Practice, 2017, 36(3), , pp.274-281 |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9QwELVKkRAXxDeBUhnENSFOnMRBQlWLqArSckCs1Fvkj3G7bOuU7K5U7vxwxo6XdlG5cIoUx5Flz9jvecbPhLxp6hpyDTKtfOCQQ2vSVjGWGhPUvyqbG384efKlPpryz8fV8RZZCyrEDlzcSO38fVLT4Sy7_PFzDx3-fUhjRm9--z2bD9qLT7ImK-uszJBq3SK3cXGqvaFPrhB_nXPE51GuZZysBW_DRYIFUiEfhy7Gcz7__rPXDxYtWn5I__JJbLguucHehFH_TrW8tnYd3if3Iuik-6OVPCBb4B6SO5MYVn9Efn0F10fFBpz9aEzyoL2lFtTqsvfHjug6XZ36vVvqA_YXfqu-P6MzR6M-62IsPEV2OwS9ovOZfEf36ZVgNB0Py1DpDD2HpUxllEV5TKaHH799OErj9QypRpS2TCsmQSvWMIOcxJhCtwyg5LWxCDIkIHICpZF-Sos4wyIw5AaUKaFtcEnUAsonZNv1Dp4RyiWTtrC6bZXlyiLrbGtTyMpCoVglbUIOfD93F6MCR-c1scOLfjjpoot13CpZGimEzTWXdS4awSFHfmdx2mG2SchrHKVurmehvn-e9N186JA5fOoQ6aIFVAl5tR7EDh3NR0-kg361wA9KIbz-YJmQp-Og_mnP2h4S0mwM90aDN0vc7DSIeSOjw9rV8_-u-YLc9eY55r3tkO3lsIKXCJSWajdsMOwGB_gNApwUiw |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Renoprotective+effects+of+febuxostat+compared+with+allopurinol+in+patients+with+hyperuricemia%3A+A+systematic+review+and+meta-analysis&rft.jtitle=Kidney+research+and+clinical+practice&rft.au=Kim%2C+Sollip&rft.au=Kim%2C+Hyun-Jung&rft.au=Ahn%2C+Hyeong-Sik&rft.au=Oh%2C+Se+Won&rft.date=2017-09-01&rft.pub=Korean+Society+of+Nephrology&rft.issn=2211-9132&rft.eissn=2211-9140&rft.volume=36&rft.issue=3&rft.spage=274&rft.epage=281&rft_id=info:doi/10.23876%2Fj.krcp.2017.36.3.274&rft_id=info%3Apmid%2F28904879&rft.externalDocID=PMC5592895 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2211-9132&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2211-9132&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2211-9132&client=summon |